RxDoctor Payments Data

Beverly Smith, DO

Internal Medicine · Abingdon, VANPI 1033609979

Payments from drug & device makers

$1,573in general payments, 2019–2025

Across 101 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$348
  • Biohaven Pharmaceutical Holding Company Ltd.$204
  • Lilly USA, LLC$198
  • AbbVie$196
  • Novo Nordisk$82
  • Gilead$78
  • plus $467 from 17 others

What the payments were for

  • Food & beverage$1,573100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,573 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$63,192
Medicare patients
157
Services billed
878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$73,128
EliquisApixaban57$48,931
JardianceEmpagliflozin30$36,231
MounjaroTirzepatide30$35,089
LinzessLinaclotide19$20,951
FarxigaDapagliflozin Propanediol14$19,682
XareltoRivaroxaban17$16,637
TrulicityDulaglutide17$15,752
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,409
SteglatroErtugliflozin Pidolate11$5,295
SymbicortBudesonide/Formoterol Fumarate13$5,248
Breo ElliptaFluticasone/Vilanterol11$5,200
LevemirInsulin Detemir12$3,389
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$2,315
Levothyroxine Sodium234$2,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Levemir$82$76,51683 claims
Lilly USA, LLCMounjaro, Trulicity$198$50,84047 claims
PfizerEliquis$348$48,93157 claims
Boehringer IngelheimJardiance$13$36,23130 claims
AstraZenecaFarxiga, Symbicort$12$24,93127 claims
AbbVieLinzess, Synthroid$196$22,28954 claims
MerckSteglatro$33$5,29511 claims
GSKBreo Ellipta$58$5,20011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Abingdon

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →